The Global Assessment of Plaque Regression with a PCSK9 Antibody as measured by Intravascular Ultrasound trial, known as the GLAGOV trial, investigated the effect of PCSK9 inhibition on atherosclerosis. This evidence concerns the gene PCSK9 and atherosclerosis.